Sunday, 09 August 2020

BIOLABEX Opens R&D Laboratory in BioPark Mauritius

23 February 2017 | News | By BioSpectrum Bureau

BIOLABEX Opens R&D Laboratory in BioPark Mauritius

A Mauritius based R&D Laboratory recently announced the launch of its development and manufacturing activities in BioPark, Mauritius. It is recently accredited as the first GMP-compliant CDMO (Contract Development and Manufacturing Organisation) in the Indian Ocean.

BIOLABEX provides full spectrum of R&D and consulting services in early development, formulation, manufacturing, concept marketing, regulatory affairs and compliance audits to its various clients in cosmetics, pharmaceutical and nutraceutical industry.

With these new activities, BIOLABEX complements the existing R&D capabilities offered in BioPark Mauritius, the first biotechnological hub in the Indian Ocean. The other key players include CIDP, an internationally recognised CRO (Contract Research Organisation), and QUANTILAB, a multi-disciplinary analytical laboratory specialised in microbiology, organic, and inorganic chemistry.

Marc LABICHE, CEO of BIOLABEX said, "Mauritius is widely regarded as one of the world's biodiversity hotspots and we saw great potential in locating our first laboratory here. We also have an office in Paris, and this dual presence allows BIOLABEX, and its clients, to draw benefits from the best of both worlds close proximity to a rich source of active ingredients, and to leading players in the pharmaceutical and cosmetics industries. These factors place BIOLABEX in a prime position to serve as a global hub."

He also added, "For now, our focus is on the cosmetics, pharmaceutical, and nutraceutical market in Europe and US, before looking towards promising markets such as Africa and Asia. Our future plans include expansion of our clientele to other industries, such as medical devices, food supplements, and agriculture."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls